Peer J:鼻腔冲洗设备效果分析

2019-06-24 AlexYang MedSci原创

鼻腔冲洗被广泛的应用于鼻疾病的辅助治疗。而关于该设备的治疗效果方面的证据还很少。最近,有研究人员基于患者和医生的经历评估了鼻冲洗设备的效果情况。研究人员在2017年11月到2018年10月进行了一个多中心的调查。研究人员收集了331台患者使用过的设备信息。患者的平均年龄为45.46±17.19岁(从5岁到81岁),男女占比分别为48.6%和51.4%。在高压设备中,研究人员发现高压大体积冲洗设备在

鼻腔冲洗被广泛的应用于鼻疾病的辅助治疗。而关于该设备的治疗效果方面的证据还很少。最近,有研究人员基于患者和医生的经历评估了鼻冲洗设备的效果情况。

研究人员在2017年11月到2018年10月进行了一个多中心的调查。研究人员收集了331台患者使用过的设备信息。患者的平均年龄为45.46±17.19岁(从5岁到81岁),男女占比分别为48.6%和51.4%。在高压设备中,研究人员发现高压大体积冲洗设备在12个模块中的7个具有显著更高的症状评分。在大体积设备中,研究发现大体积高压冲洗设备在12个模块中的4个具有显著更高的症状得分(p<0.05)。然而,使用大体积高压鼻冲洗设备的患者在鼻窦内保留液体的比例要比使用大体积低压设备的患者比例显著更高(p<0.001)。

最后,研究人员指出,他们的调查支持了鼻冲洗设备的的常规使用,尤其是大体积高压设备作为鼻疾病的有效治疗方法。它能够在清除鼻分泌物、改善鼻塞、减少鼻液倒流、改善鼻窦疼痛或者头痛、改善味觉和嗅觉以及改善睡眠治疗中起到积极的作用。

原始出处:

Piromchai P, Puvatanond C, Kirtsreesakul V et al. Effectiveness of nasal irrigation devices: a Thai multicentre survey. Peer J. 27 May 2019

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1786932, encodeId=6d771e869320b, content=<a href='/topic/show?id=3bd213998ca' target=_blank style='color:#2F92EE;'>#peer#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13998, encryptionId=3bd213998ca, topicName=peer)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=917c196, createdName=sjzlzc007, createdTime=Fri Aug 09 08:12:00 CST 2019, time=2019-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1910991, encodeId=e0e0191099182, content=<a href='/topic/show?id=e6045e517dd' target=_blank style='color:#2F92EE;'>#效果分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57517, encryptionId=e6045e517dd, topicName=效果分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sun Jul 21 16:12:00 CST 2019, time=2019-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728030, encodeId=3b6e1e280303f, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Mon Feb 03 21:12:00 CST 2020, time=2020-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1739943, encodeId=95441e3994326, content=<a href='/topic/show?id=f49c310e134' target=_blank style='color:#2F92EE;'>#冲洗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31071, encryptionId=f49c310e134, topicName=冲洗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ec334602181, createdName=ms3892185887221420, createdTime=Thu Mar 19 19:12:00 CST 2020, time=2020-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465856, encodeId=2afe146585656, content=<a href='/topic/show?id=736b103508c6' target=_blank style='color:#2F92EE;'>#鼻腔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103508, encryptionId=736b103508c6, topicName=鼻腔)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=224e6763385, createdName=mnda, createdTime=Wed Jun 26 04:12:00 CST 2019, time=2019-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1046856, encodeId=8d6810468564f, content=疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Mon Jun 24 16:12:00 CST 2019, time=2019-06-24, status=1, ipAttribution=)]
    2019-08-09 sjzlzc007
  2. [GetPortalCommentsPageByObjectIdResponse(id=1786932, encodeId=6d771e869320b, content=<a href='/topic/show?id=3bd213998ca' target=_blank style='color:#2F92EE;'>#peer#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13998, encryptionId=3bd213998ca, topicName=peer)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=917c196, createdName=sjzlzc007, createdTime=Fri Aug 09 08:12:00 CST 2019, time=2019-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1910991, encodeId=e0e0191099182, content=<a href='/topic/show?id=e6045e517dd' target=_blank style='color:#2F92EE;'>#效果分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57517, encryptionId=e6045e517dd, topicName=效果分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sun Jul 21 16:12:00 CST 2019, time=2019-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728030, encodeId=3b6e1e280303f, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Mon Feb 03 21:12:00 CST 2020, time=2020-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1739943, encodeId=95441e3994326, content=<a href='/topic/show?id=f49c310e134' target=_blank style='color:#2F92EE;'>#冲洗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31071, encryptionId=f49c310e134, topicName=冲洗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ec334602181, createdName=ms3892185887221420, createdTime=Thu Mar 19 19:12:00 CST 2020, time=2020-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465856, encodeId=2afe146585656, content=<a href='/topic/show?id=736b103508c6' target=_blank style='color:#2F92EE;'>#鼻腔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103508, encryptionId=736b103508c6, topicName=鼻腔)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=224e6763385, createdName=mnda, createdTime=Wed Jun 26 04:12:00 CST 2019, time=2019-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1046856, encodeId=8d6810468564f, content=疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Mon Jun 24 16:12:00 CST 2019, time=2019-06-24, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1786932, encodeId=6d771e869320b, content=<a href='/topic/show?id=3bd213998ca' target=_blank style='color:#2F92EE;'>#peer#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13998, encryptionId=3bd213998ca, topicName=peer)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=917c196, createdName=sjzlzc007, createdTime=Fri Aug 09 08:12:00 CST 2019, time=2019-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1910991, encodeId=e0e0191099182, content=<a href='/topic/show?id=e6045e517dd' target=_blank style='color:#2F92EE;'>#效果分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57517, encryptionId=e6045e517dd, topicName=效果分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sun Jul 21 16:12:00 CST 2019, time=2019-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728030, encodeId=3b6e1e280303f, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Mon Feb 03 21:12:00 CST 2020, time=2020-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1739943, encodeId=95441e3994326, content=<a href='/topic/show?id=f49c310e134' target=_blank style='color:#2F92EE;'>#冲洗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31071, encryptionId=f49c310e134, topicName=冲洗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ec334602181, createdName=ms3892185887221420, createdTime=Thu Mar 19 19:12:00 CST 2020, time=2020-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465856, encodeId=2afe146585656, content=<a href='/topic/show?id=736b103508c6' target=_blank style='color:#2F92EE;'>#鼻腔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103508, encryptionId=736b103508c6, topicName=鼻腔)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=224e6763385, createdName=mnda, createdTime=Wed Jun 26 04:12:00 CST 2019, time=2019-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1046856, encodeId=8d6810468564f, content=疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Mon Jun 24 16:12:00 CST 2019, time=2019-06-24, status=1, ipAttribution=)]
    2020-02-03 feather89
  4. [GetPortalCommentsPageByObjectIdResponse(id=1786932, encodeId=6d771e869320b, content=<a href='/topic/show?id=3bd213998ca' target=_blank style='color:#2F92EE;'>#peer#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13998, encryptionId=3bd213998ca, topicName=peer)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=917c196, createdName=sjzlzc007, createdTime=Fri Aug 09 08:12:00 CST 2019, time=2019-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1910991, encodeId=e0e0191099182, content=<a href='/topic/show?id=e6045e517dd' target=_blank style='color:#2F92EE;'>#效果分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57517, encryptionId=e6045e517dd, topicName=效果分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sun Jul 21 16:12:00 CST 2019, time=2019-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728030, encodeId=3b6e1e280303f, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Mon Feb 03 21:12:00 CST 2020, time=2020-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1739943, encodeId=95441e3994326, content=<a href='/topic/show?id=f49c310e134' target=_blank style='color:#2F92EE;'>#冲洗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31071, encryptionId=f49c310e134, topicName=冲洗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ec334602181, createdName=ms3892185887221420, createdTime=Thu Mar 19 19:12:00 CST 2020, time=2020-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465856, encodeId=2afe146585656, content=<a href='/topic/show?id=736b103508c6' target=_blank style='color:#2F92EE;'>#鼻腔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103508, encryptionId=736b103508c6, topicName=鼻腔)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=224e6763385, createdName=mnda, createdTime=Wed Jun 26 04:12:00 CST 2019, time=2019-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1046856, encodeId=8d6810468564f, content=疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Mon Jun 24 16:12:00 CST 2019, time=2019-06-24, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1786932, encodeId=6d771e869320b, content=<a href='/topic/show?id=3bd213998ca' target=_blank style='color:#2F92EE;'>#peer#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13998, encryptionId=3bd213998ca, topicName=peer)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=917c196, createdName=sjzlzc007, createdTime=Fri Aug 09 08:12:00 CST 2019, time=2019-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1910991, encodeId=e0e0191099182, content=<a href='/topic/show?id=e6045e517dd' target=_blank style='color:#2F92EE;'>#效果分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57517, encryptionId=e6045e517dd, topicName=效果分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sun Jul 21 16:12:00 CST 2019, time=2019-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728030, encodeId=3b6e1e280303f, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Mon Feb 03 21:12:00 CST 2020, time=2020-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1739943, encodeId=95441e3994326, content=<a href='/topic/show?id=f49c310e134' target=_blank style='color:#2F92EE;'>#冲洗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31071, encryptionId=f49c310e134, topicName=冲洗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ec334602181, createdName=ms3892185887221420, createdTime=Thu Mar 19 19:12:00 CST 2020, time=2020-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465856, encodeId=2afe146585656, content=<a href='/topic/show?id=736b103508c6' target=_blank style='color:#2F92EE;'>#鼻腔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103508, encryptionId=736b103508c6, topicName=鼻腔)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=224e6763385, createdName=mnda, createdTime=Wed Jun 26 04:12:00 CST 2019, time=2019-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1046856, encodeId=8d6810468564f, content=疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Mon Jun 24 16:12:00 CST 2019, time=2019-06-24, status=1, ipAttribution=)]
    2019-06-26 mnda
  6. [GetPortalCommentsPageByObjectIdResponse(id=1786932, encodeId=6d771e869320b, content=<a href='/topic/show?id=3bd213998ca' target=_blank style='color:#2F92EE;'>#peer#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13998, encryptionId=3bd213998ca, topicName=peer)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=917c196, createdName=sjzlzc007, createdTime=Fri Aug 09 08:12:00 CST 2019, time=2019-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1910991, encodeId=e0e0191099182, content=<a href='/topic/show?id=e6045e517dd' target=_blank style='color:#2F92EE;'>#效果分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57517, encryptionId=e6045e517dd, topicName=效果分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sun Jul 21 16:12:00 CST 2019, time=2019-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728030, encodeId=3b6e1e280303f, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Mon Feb 03 21:12:00 CST 2020, time=2020-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1739943, encodeId=95441e3994326, content=<a href='/topic/show?id=f49c310e134' target=_blank style='color:#2F92EE;'>#冲洗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31071, encryptionId=f49c310e134, topicName=冲洗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ec334602181, createdName=ms3892185887221420, createdTime=Thu Mar 19 19:12:00 CST 2020, time=2020-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465856, encodeId=2afe146585656, content=<a href='/topic/show?id=736b103508c6' target=_blank style='color:#2F92EE;'>#鼻腔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103508, encryptionId=736b103508c6, topicName=鼻腔)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=224e6763385, createdName=mnda, createdTime=Wed Jun 26 04:12:00 CST 2019, time=2019-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1046856, encodeId=8d6810468564f, content=疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Mon Jun 24 16:12:00 CST 2019, time=2019-06-24, status=1, ipAttribution=)]
    2019-06-24 CHANGE

    疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的

    0

相关资讯

盘点:鼻炎治疗进展

【1】Allergy Asthma Proc:奥洛他定-莫米松组合鼻喷剂在季节过敏性鼻炎患者中的效果和安全性评估 GSP301是一种研究用的固定剂量组合鼻喷剂,其中包含了抗组胺剂、盐酸洛普他定(HCI)和皮质类固醇糠酸莫米他松。最近,有研究人员评估了GSP301在季节过敏性鼻炎(SAR)患者中的效果和安全性。研究是一个双盲、随机和平行的研究。研究总共包括了1180名患者。在经过14天

JIACI:高剂量猫和狗提取物的皮下免疫疗法研究

目前关于对猫和狗过敏的免疫治疗方法的有效数据还很少。最近,有研究人员评估了皮下免疫疗法(SCIT)对猫和狗过敏患者治疗的安全性和效果。研究是一个务实的、真实生活的和前瞻性的观察性研究。所有的患者对猫和狗都具有特异性的lgE。研究人员使用一种输液泵(IP)进行SCIT注射。研究包括了66名患者,38名女性,46名对猫过敏,20名对狗过敏,年龄范围从9岁到59岁。在加药阶段研究人员使用了输液泵,且8.

Am J Rhinol Allergy:鼻腔细胞学作为局部过敏性鼻炎的诊断工具分析

局部过敏性鼻炎(LAR)可以通过皮刺试验(SPT)或者特异性血清lgE水平进行评估,具体表现为慢性鼻炎对过敏原的局部鼻过敏响应,且不存在全身免疫球蛋白(lgE)调控的疾病。鼻激发试验(NPT)是LAR诊断的黄金标准。鼻嗜酸性粒细胞是一种已知的过敏性鼻炎炎症标记。最近,有研究人员认为鼻嗜酸性粒细胞可以作为LAR的一种筛选标记并进行了验证。研究包括了48名具有常年非过敏性鼻炎(NAR)患者,且SPT为

盘点:鼻炎的分子机制进展

【1】EBioMedicine:IL-2响应的减少与总lgE水平提高和过敏性鼻炎的加重相关 自身免疫和过敏与调节T细胞(Tregs)数目的减少和低水平的白介素-2(IL-2)相关。最近,有研究人员调查了在童年早期,是否病原气道细菌刺激外周血单核细胞(PBMCs)而释放的IL-2与过敏结果的发展相关。研究人员从331名6月大的婴幼儿中分离了PBMCs细胞,之后在体外利用流感嗜血杆菌、卡他拉

Int Immunopharmacol:TLR4拮抗剂能够减轻并发过敏性鼻炎和哮喘综合症

最近,有研究人员调查了TLR4拮抗剂在卵清蛋白(OVA)诱导的并发过敏性鼻炎和哮喘综合症(CARAS)小鼠模型中的影响情况。研究人员建立了一个OVA诱导的小鼠CARAS模型,并将TLR4拮抗剂,TAK-242进行鼻内或者腹腔内注射,并利用流式细胞仪、蛋白免疫印迹和酶联免疫反应(ELISA)对不同细胞类型数目、相关蛋白的表达和相关白介素水平进行了检测。研究发现,TAK-242处理能够下调CCL2的表

J Microbiol Immunol Infect:早发性湿疹与牛奶过敏、鼻炎和哮喘风险的增加相关

过敏性湿疹和食物过敏经常在儿童早期发生。然而,湿疹起始与过敏原敏感有关的特应性疾病的发生的相关性的关系仍旧不清楚。最近,有研究人员跟踪调查了186名儿童,跟踪调查为期4年。研究人员将儿童分成3个小组:早发性湿疹组(小于2岁,n=55),晚发性湿疹组(不小于2岁,n=40)和不具有湿疹组(n=91)。研究发现,在具有早发性湿疹组中,食物过敏,尤其是牛奶过敏患病率与1、1.5、2、3和4岁的没有湿疹的